Tag: patients

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

Data from Orbit and Cosmic studies expected around the end of the year

RIYADH, Saudi Arabia, July 09, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient and a healthcare institution, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has continued to support a patient since infancy, providing 22 years of continuous care for a rare genetic blood clotting disorder, ultimately culminating in a liver transplant—the first of its kind globally for this particular condition.

Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval